NCT05881785View on ClinicalTrials.gov

Study of Efficacy and Safety of GR1501 in Patients with Radiographic Axial Spondyloarthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

465

Participants

Timeline

Start Date

June 13, 2022

Primary Completion Date

December 18, 2023

Study Completion Date

May 21, 2024

Conditions
Axial Spondyloarthritis
Interventions
BIOLOGICAL

GR1501 low dose

3×low dose GR1501 every 2 weeks,then low dose GR1501 monthly

BIOLOGICAL

GR1501 high dose

3×high dose GR1501 every 2 weeks,then high dose GR1501 monthly

BIOLOGICAL

placebo

"* Core treatment period:placebo~* Maintenance treatment period: GR1501 injection"

Trial Locations (1)

100730

Peking union Medical Hosipital, Beijing

All Listed Sponsors
lead

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

INDUSTRY